Top Markets
Coin of the day
Duality Biotherapeutics, Inc. Duality Biotherapeutics, Inc.

Duality Biotherapeutics, Inc.

9606
Rank in Stocks #6046
Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc.... Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc. concentrates on pioneering next-generation antibody-drug conjugate (ADC) therapies and proprietary duality immune toxin antibody conjugate (ITAC) solutions. The firm was founded by Zhu Zhong Yuan on July 3, 2019, and its main offices are situated in Shanghai, China.
Share Price
$25.01
Market Cap
$2.26B
Change (1 day)
-1.21%
Change (1 year)
-37.74%
Country
CN
Trade Duality Biotherapeutics, Inc. (9606)

Category

Revenue for Duality Biotherapeutics, Inc. (9606)
Revenue in Aug 2026 TTM: 0
According to Duality Biotherapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Duality Biotherapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
$15.74B -
AU
$2.23B -
US
- -
CH